Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of a novel class of DARPin therapeutics, a novel class of custom-built protein drugs, for medical challenges that other drug modalities cannot readily address.
Cooperation possibilities
Molecular Partners has entered several agreements with pharma and biotech companies such as Allergan and Amgen. The company is actively seeking further partnerships for the co-development of innovative therapeutic products based on its innovative DARPin® platform.
- http://www.molecularpartners.com
- +41 44 755 77 00
- info@molecularpartners.com
- Patrick Amstutz, CEO
